Enrolling By Invitation PHASE1 INTERVENTIONAL 1-arm
NCT06902792
Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents
A Single-Center, Single-Arm, Phase I Clinical Trial of Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents
Sponsor: Second Affiliated Hospital of Wenzhou Medical University
Conditions
Histiocytosis, Langerhans-Cell
Interventions
treated group
Updated 1 time since 2025 Last updated: Mar 24, 2025 Started: Feb 6, 2025 Primary completion: Aug 6, 2025 Completion: Feb 2, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06902792, this PHASE1 trial focuses on Histiocytosis, Langerhans-Cell and remains ongoing. Sponsored by Second Affiliated Hospital of Wenzhou Medical University, it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Enrolling By Invitation — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Second Affiliated Hospital of Wenzhou Medical University
Data source: Second Affiliated Hospital of Wenzhou Medical University
For direct contact, visit the study record on ClinicalTrials.gov .